1
|
Wang X, Xiong W, Li M, Wu L, Zhang Y, Zhu C, Lin W, Chen S, Huang H. Role of inflammatory cytokine in mediating the effect of plasma lipidome on epilepsy: a mediation Mendelian randomization study. Front Neurol 2024; 15:1388920. [PMID: 38872823 PMCID: PMC11169836 DOI: 10.3389/fneur.2024.1388920] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2024] [Accepted: 05/13/2024] [Indexed: 06/15/2024] Open
Abstract
Background Epilepsy is one of the most prevalent serious brain disorders globally, impacting over 70 million individuals. Observational studies have increasingly recognized the impact of plasma lipidome on epilepsy. However, establishing a direct causal link between plasma lipidome and epilepsy remains elusive due to inherent confounders and the complexities of reverse causality. This study aims to investigate the causal relationship between specific plasma lipidome and epilepsy, along with their intermediary mediators. Methods We conducted a two-sample Mendelian randomization (MR) and mediation MR analysis to evaluate the causal effects of 179 plasma lipidomes and epilepsy, with a focus on the inflammatory cytokine as a potential mediator based on the genome-wide association study. The primary methodological approach utilized inverse variance weighting, complemented by a range of other estimators. A set of sensitivity analyses, including Cochran's Q test, I 2 statistics, MR-Egger intercept test, MR-PRESSO global test and leave-one-out sensitivity analyses was performed to assess the robustness, heterogeneity and horizontal pleiotropy of results. Results Our findings revealed a positive correlation between Phosphatidylcholine (18:1_18:1) levels with epilepsy risk (OR = 1.105, 95% CI: 1.036-1.178, p = 0.002). Notably, our mediation MR results propose Tumor necrosis factor ligand superfamily member 12 levels (TNFSF12) as a mediator of the relationship between Phosphatidylcholine (18,1_18:1) levels and epilepsy risk, explaining a mediation proportion of 4.58% [mediation effect: (b = 0.00455, 95% CI: -0.00120-0.01030), Z = 1.552]. Conclusion Our research confirms a genetic causal relationship between Phosphatidylcholine (18:1_18:1) levels and epilepsy, emphasizing the potential mediating role of TNFSF12 and provide valuable insights for future clinical investigations into epilepsy.
Collapse
Affiliation(s)
- Xiangyi Wang
- Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China
| | - Wenting Xiong
- Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China
| | - Man Li
- Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China
| | - Luyan Wu
- Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China
| | - Yuying Zhang
- Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China
| | - Chaofeng Zhu
- Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China
| | - Wanhui Lin
- Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China
| | - Shenggen Chen
- Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China
| | - Huapin Huang
- Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China
- Fujian Key Laboratory of Molecular Neurology, Fuzhou, China
- Department of Geriatrics, Fujian Medical University Union Hospital, Fuzhou, China
| |
Collapse
|
2
|
Nguyen QA, Klein PM, Xie C, Benthall KN, Iafrati J, Homidan J, Bendor JT, Dudok B, Farrell JS, Gschwind T, Porter CL, Keravala A, Dodson GS, Soltesz I. Acetylcholine receptor based chemogenetics engineered for neuronal inhibition and seizure control assessed in mice. Nat Commun 2024; 15:601. [PMID: 38238329 PMCID: PMC10796428 DOI: 10.1038/s41467-024-44853-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2023] [Accepted: 01/09/2024] [Indexed: 01/22/2024] Open
Abstract
Epilepsy is a prevalent disorder involving neuronal network hyperexcitability, yet existing therapeutic strategies often fail to provide optimal patient outcomes. Chemogenetic approaches, where exogenous receptors are expressed in defined brain areas and specifically activated by selective agonists, are appealing methods to constrain overactive neuronal activity. We developed BARNI (Bradanicline- and Acetylcholine-activated Receptor for Neuronal Inhibition), an engineered channel comprised of the α7 nicotinic acetylcholine receptor ligand-binding domain coupled to an α1 glycine receptor anion pore domain. Here we demonstrate that BARNI activation by the clinical stage α7 nicotinic acetylcholine receptor-selective agonist bradanicline effectively suppressed targeted neuronal activity, and controlled both acute and chronic seizures in male mice. Our results provide evidence for the use of an inhibitory acetylcholine-based engineered channel activatable by both exogenous and endogenous agonists as a potential therapeutic approach to treating epilepsy.
Collapse
Affiliation(s)
- Quynh-Anh Nguyen
- Department of Neurosurgery, Stanford University, Stanford, CA, 94305, USA.
| | - Peter M Klein
- Department of Neurosurgery, Stanford University, Stanford, CA, 94305, USA.
| | - Cheng Xie
- CODA Biotherapeutics, 240 East Grand Ave., South San Francisco, CA, 94080, USA
| | - Katelyn N Benthall
- CODA Biotherapeutics, 240 East Grand Ave., South San Francisco, CA, 94080, USA
| | - Jillian Iafrati
- CODA Biotherapeutics, 240 East Grand Ave., South San Francisco, CA, 94080, USA
| | - Jesslyn Homidan
- Department of Neurosurgery, Stanford University, Stanford, CA, 94305, USA
| | - Jacob T Bendor
- CODA Biotherapeutics, 240 East Grand Ave., South San Francisco, CA, 94080, USA
| | - Barna Dudok
- Department of Neurosurgery, Stanford University, Stanford, CA, 94305, USA
- Department of Neurology, Baylor College of Medicine, Houston, TX, 77030, USA
| | - Jordan S Farrell
- Department of Neurosurgery, Stanford University, Stanford, CA, 94305, USA
| | - Tilo Gschwind
- Department of Neurosurgery, Stanford University, Stanford, CA, 94305, USA
| | - Charlotte L Porter
- Department of Neurosurgery, Stanford University, Stanford, CA, 94305, USA
| | - Annahita Keravala
- CODA Biotherapeutics, 240 East Grand Ave., South San Francisco, CA, 94080, USA
| | - G Steven Dodson
- CODA Biotherapeutics, 240 East Grand Ave., South San Francisco, CA, 94080, USA
| | - Ivan Soltesz
- Department of Neurosurgery, Stanford University, Stanford, CA, 94305, USA
| |
Collapse
|